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Purpose: The cognitive side effects of whole brain radiotherapy 
(WBRT) are well recognized, as is the importance of local disease 
control on neurocognitive function. We therefore set out to 
assess the neurocognitive impact of a central nervous system 
(CNS) event in patients that received volumetric radiosurgery 
(VRS) and WBRT to aid in defining a subgroup of patients 
receiving radiosurgery that may preserve cognition with WBRT. 
Methods and Materials: This multicentre Phase 2, single-arm 
study accrued 60 patients with one to ten brain metastases. 
Eligible patients received 47.5 Gy in 5 fractions VRS to their 
metastases concurrent with 20 Gy in 5 fractions to the whole 
brain. Cognitive assessment was a secondary endpoint in the 
trial. Neurocognitive function was assessed using the Mini-Mental 
State Examination (MMSE). It was analyzed at baseline and at 
three-month intervals, until the 12-month follow up point. An 
MMSE drop of 3 points, which is the minimal clinically significant 
difference, was defined as a cognitive event. A CNS event was 
defined as local recurrence, distant brain relapse or 
radionecrosis. 
Results: From July 2010 to May 2013, 60 patients, with a median 
age of 62 years, underwent treatment. Median survival was 10.1 
months. Twenty-seven patients (45%) had a CNS event in the first 
12 months after treatment. Sixteen patients (59%) developed 
distant brain relapse, five (19%) local relapse, and six (22%) 
radionecrosis. On univariate analysis, the risk of a CNS event 
(hazard ratio (HR = 5.4, p = 0.03). was significantly associated 
with the risk of first 3 point drop in MMSE. On multivariate 
analysis, both age (HR = 4.5, p = 0.03) and CNS event (HR =11.6, 
p = 0.03) were significantly associated with a cognitive event. 
The risk of a first 3-point drop in MMSE was found to be highest 
in patients above median age that experienced a CNS event. 
Conclusions: The results of this study showed that control of CNS 
events is the most import factor in maintaining neurocognitive 
function in patients with one to ten brain metastases. It 
determined that a clinically significant drop in MMSE was 
associated with local recurrence, distant brain relapse or 
radionecrosis, as well as older age. In patients treated with 
WBRT, it highlights the importance of age on neurocognitive 
function, as older patients with a CNS event were more at risk of 
a cognitive event. Using WBRT adjuvantly to preserve cognitive 
function, should be considered in younger patients with a high-
risk of distant brain relapse. 
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Introduction:  Randomized Controlled Trials (RCT), particularly 
of rare tumour groups, often have issues with patient accrual, 
which necessitates a multicentre approach to achieve accrual 
targets. Logistically, investigators of multicentre trials face 
issues in efficient data management in terms of accuracy, 
transfer, security, and quality assurance. Historically, paper-
based report forms to collect patient baseline and regular follow 
up data have made these issues challenging. 
Purpose: To discuss the use of electronic forms (eForms) used 
for our glioblastoma multiforme (GBM) trial study. Various 
limitations and advantages of the use of eForms are discussed 
and compared to paper based and other internet based data 
collection methods 
Methods and Materials: Specially formatted computer based PDF 
forms were completed to gather patient by the investigators for 
screening and eligibility data (eForm A and B), as well as baseline 
QOL eForms (quality of life data according to EORTC QLQ-C30 
and QLQ-BN20 questionnaires). After randomization, radiation 
treatment details (eForm C) and QOL data were collected. eForm 
D was used to collect follow up data. All of these forms were 
completed by the participating centre and then emailed as an 
attachment to the Data Management Centre (DMC). A short 
satisfaction survey was sent to the physicians of the participating 
centres after the completion of the study. 
Results: For this study, there were 12 participating centres from 
around the world. There were no issues overall with data 
collection using the eForms. The costs associated with the 
development of the eForms were minimal as well. The forms 
were a convenient way of sending patient trial data via email to 
the DMC. The results of the short survey agree with our 
experience. About 90% of the participating sites found the design 
of the forms to be user-friendly, and did not have any problems 
accessing, completing, and submitting the files from their 
computer. Most of the participants found the eForms to be very 
practical, efficient, and standardized. About 20% of the 
participants found the need for a guide to be associated with the 
eForms for better standardization and minimizing bias. We did 
not find any problems with the security of using eForms as well.  
Conclusions:  In the setting of multicentre trials, using eForms 
for data management proved to be efficient, convenient, and 
reliable. Future multicentre trials may benefit from similar data 
management systems to improve data collection and analysis. 
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Purpose: Stereotactic ablative radiotherapy (SABR) is a 
guideline-specified treatment option for early-stage lung cancer. 
However, significant post-treatment fibrosis can occur and 
confound the detection of local recurrence. The goal of this 
study was to assess physician ability to detect timely local 
recurrence on computed tomography (CT) imaging, and compare 
physician performance with that of a radiomics tool. Radiomics 
aims to extract more complex information from medical images, 
including features not easily visible with the naked eye. 
Methods and Materials: CT scans of 45 patients (15 with proven 
local recurrence matched to 30 with no local recurrence) were 
used to measure physician and radiomic performance in assessing 
response. Scans were individually scored by three thoracic 
radiation oncologists and three thoracic radiologists, all of whom 
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were blinded to clinical outcomes. Radiomic features (first-
order, second-order grey-level co-occurrence matrix, and size- 
and shape-based) were extracted from the same images. 
Performance of the physician assessors and the radiomics 
signatures were compared.  
Results: A total of 182 follow up CT scans were analyzed with a 
median imaging follow up of 20 months. When taking into 
account all CT scans during the entire follow up period, median 
sensitivity for physician assessment of local recurrence was 83% 
(range 67–100%) and specificity was 75% (range 67–87%), with 
only moderate inter-observer agreement (kappa=0.54). The 
median time to detection of recurrence across all observers was 
15.5 months. When predicting recurrence using images acquired 
< 6 months post-SABR, physicians assessed the majority of images 
as benign injury/no recurrence, with a mean error of 35%, false 
positive rate (FPR) of 1%, and false negative rate (FNR) of 99%. 
At the same time point, a radiomic signature consisting of five 
post-SABR image appearance features in the consolidative and 
surrounding peri-consolidative regions demonstrated excellent 
discrimination, with an area under the receiver operating 
characteristic curve of 0.85, leave-one-out cross-validation 
classification error of 24%, FPR of 24%, and FNR of 23%.  
Conclusions: These results suggest that radiomics can detect 
early changes associated with local recurrence that are not 
typically considered by physicians. Patients with recurrence tend 
to have increased presence of ground-glass opacity surrounding 
consolidative changes compared to patients with benign injury 
at this early follow up time point. These appearances detected 
by radiomics may be early indicators of the promotion and 
progression to local recurrence; our ongoing studies include using 
correlative histology to determine their composition. This has 
the potential to lead to a clinically useful computer aided 
decision support tool based on routinely acquired CT imaging, 
which could lead to earlier life-saving salvage opportunities for 
patients with local recurrence following SABR. 
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Purpose: A fused deposition modeling three dimensional printer 
is currently being commissioned at our centre for fabrication of 
electron bolus. The main advantage in using a 3D printer for this 
purpose is that virtually any shape can be produced, potentially 
providing a more accurate way to compensate for irregular 
surfaces that can change the dose distribution within the 
patient. PLA is one of the most commonly used 3D printer 
materials. Compared to ABS, PLA is less likely to warp due to 
heating and cooling during printing. For less expensive printers 
which may not have heated printing beds or thermally controlled 
environments, it is especially appealing. Before PLA boluses can 
be clinically used, their physical and dosimetric properties must 
be characterized. The purpose of this study was to characterize 
the density, dimensional accuracy, uniformity, and attenuation 
of PLA boluses fabricated with our printer. 
Methods and Materials: Several uniform solid square slabs were 
printed with specific requested dimensions and 100% infill using 
concentric and rectilinear fill patterns. These pieces were 
imaged using an x-ray flat panel imager in order to check for 
uniformity of the print. The PLA slabs were placed on solid water 
and irradiated with a 12 MeV electron beam. Percentage depth 
doses (PDDs) were measured downstream of the slabs using a 
parallel plate chamber and compared to measurements in water. 
The dimensions of the PLA slabs were measured using digital 
calipers in several locations, and the average was compared to 
design values. The slabs were also weighed using a digital scale 
to find their average density relative to water. 
Results: X-ray imaging showed that certain fill patterns can 
create local errors in density where the printer’s extruder 
changes direction. This can produce significant changes in dose - 
in one case there was a > 10% surface dose directly under the 
defect. Fill patterns which eliminate changes in extruder 
direction in sensitive regions (e.g. a rectilinear pattern) 
eliminated such defects. PLA causes the electron PDD to shift 
towards shallower depths, compared to water, by 1.7 mm for 
each centimeter of PLA due to its increased density. This can be 
taken into account during treatment planning, provided the 
thickness of PLA is roughly constant over the area to be treated. 
This may not be the case if treating very large regions with 
complex contours. Agreement with design dimensions was within 
1 mm in the plane of the printer bed, and within 1/3 of a 
millimeter (roughly the thickness of a single layer), 
perpendicular to the printer bed. Average density relative to 
water was in the range 1.20 – 1.22. 
Conclusions: 3D printing shows great promise for use in 
fabricating electron bolus. This work indicates that PLA can be a 
suitable material provided the increased attenuation is properly 
accounted for. 
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Purpose: To develop and test a radiochromic-based in-vivo skin 
dosimetry protocol for permanent breast 103Pd seed implant 
brachytherapy (PBSI) and to compare measured doses with the 
calculated by a commercial TG43-based treatment planning 
system.  
Methods and Materials: EBT3 radiochromic films were calibrated 
using an ad-hoc acrylic phantom and 103Pd seeds. EBT3 films 
strips from the calibrated EBT3 batch and measuring 
approximately 2x15 cm2 were positioned directly over the breast 
skin of 13 patients implanted with103Pd seeds. The EBT3 
filmstrips were positioned immediately after the PBSI procedure 
and were centred on the skin projection of the patient’s seroma 
and were fixed to the breast skin of the patients using 
TransporeTM film. No gauze or any other material was placed on 
top of the EBT3 filmstrip. However, a TagadermTM transparent 
film dressing was placed over the area of the implant to prevent 
direct contact of the EBT3 filmstrip with the patient’s skin. The 
average exposure time for the films was four hours. The films 
were evaluated at least 24 hours after exposure following an in 
house EBT3 radiochromic evaluation protocol. The maximum 
actual measured dose defined as the 10x10 mm2 region that 
exhibited the maximum net optical density on the filmstrip was 
used to estimate the dose to the breast skin by integration over 
the life of the 103Pd seeds. The maximum dose to the skin at the 
filmstrip position was also calculated using the TG43-based MIM 
MAESTROTM treatment planning system (TPS). A structure 
extending 0.5 mm from the body was constructed to mimic the 
filmstrip, at position at a similar location with respect to the 
seroma. The dose within the filmstrip was obtained as the 
maximum dose to a volume of 10x10x0.5 mm3 (0.05 cm3).  
Results: In general the dose calculations underestimated the 
EBT3-based measurements. For the highest dose measured (81.3 
± 4.9 and 82.3 ± 3.0 Gy) the corresponding calculated doses were 
slightly lower (7% on average). For the intermediate dose range 
(40 to 60 Gy, seven patients) the dose calculations were 
approximately 50% lower than the measured doses. For the 
lowest doses measured (20-40 Gy, four patients), the calculated 
dose were on average 15% lower than the measured. The good 
agreement at high and low doses is unexpected given the 
expected dose overestimation of the TG43-based TPS. The large 
